● Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma · Sponsor: AstraZeneca

PhasePhase 3

Planned participants1220

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (220)

Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	Tucson, Arizona, United States	Recruiting
Research Site	Los Angeles, California, United States	Not Yet Recruiting
Research Site	Palo Alto, California, United States	Recruiting
Research Site	New Haven, Connecticut, United States	Recruiting
Research Site	Newark, Delaware, United States	Recruiting
Research Site	Jacksonville, Florida, United States	Recruiting
Research Site	Atlanta, Georgia, United States	Recruiting
Research Site	Atlanta, Georgia, United States	Withdrawn
Research Site	Honolulu, Hawaii, United States	Withdrawn
Research Site	Chicago, Illinois, United States	Not Yet Recruiting
Research Site	Indianapolis, Indiana, United States	Not Yet Recruiting

+ 208 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06921785